Immunodiagnostic Systems Holdings PLC
GPTKB entity
Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:IDEXX_Laboratories_Inc.
|
| gptkbp:acquisition |
Acquired by the private equity firm in 2018
|
| gptkbp:ceo |
gptkb:Graham_Mullis
|
| gptkbp:employees |
Approximately 200
|
| gptkbp:focus |
In-vitro diagnostics
|
| gptkbp:founded |
gptkb:2004
|
| gptkbp:headquarters |
Newcastle upon Tyne, United Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunodiagnostic Systems Holdings PLC
|
| gptkbp:industry |
Medical Diagnostics
|
| gptkbp:market |
Global market
|
| gptkbp:partnerships |
Collaborations with research institutions
|
| gptkbp:products |
Immunoassay systems
|
| gptkbp:research_focus |
Infectious diseases
Endocrinology Autoimmunity Bone metabolism |
| gptkbp:revenue |
£30 million (2020)
|
| gptkbp:services |
Diagnostic testing services
|
| gptkbp:stock_exchange |
gptkb:London_Stock_Exchange
|
| gptkbp:subsidiary |
IDS France
IDS Germany IDSUSA |
| gptkbp:traded_on |
IDH
|
| gptkbp:website |
www.idsplc.com
|